Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Surgery Today
Published in: Surgery Today 12/2016

01-12-2016 | Original Article

The effects of bevacizumab on intestinal anastomotic healing in rabbits

Authors: Hayato Nakamura, Yukihiro Yokoyama, Keisuke Uehara, Toshio Kokuryo, Junpei Yamaguchi, Toyonori Tsuzuki, Masato Nagino

Published in: Surgery Today | Issue 12/2016

Login to get access

Abstract

Purposes

The aim of this study was to investigate the effects of the preoperative administration of BV on the healing process of intestinal anastomosis in a rabbit model.

Methods

Twenty male white rabbits were randomly divided into two groups. The control group received saline 1 week before surgery, and the BV group received intravenous BV 1 week before surgery. Each rabbit underwent an enteroenterostomy and a colocolostomy. On postoperative day 7, the bursting pressures of the anastomoses, CD31 and α-smooth muscle actin (α-SMA) staining by immunohistochemistry, the gene expression of α-SMA, and collagen deposition using Picrosirius Red at the site of anastomosis were evaluated.

Results

The bursting pressure of small bowel anastomoses was significantly lower in the BV group than in the control group (control 184 ± 10 mmHg vs. BV 140 ± 9 mmHg; p = 0.004). The microvessel counts in the anastomotic tissue were significantly lower in the BV group than in the control group in both the small bowel (p = 0.023) and colon (p = 0.008). The expression of α-SMA, and the degree of collagen deposition decreased in the anastomotic tissue in the BV group compared with the control group.

Conclusion

The preoperative use of BV may therefore negatively affect the rigidity of intestinal anastomosis.
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (J Int Cancer). 2010;127:2893–917.CrossRef
2.
Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.CrossRefPubMed
3.
Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28:4697–705.CrossRefPubMed
4.
Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987–9.CrossRefPubMed
5.
Hofland KF, Hansen S, Sorensen M, Engelholm S, Schultz HP, Muhic A, et al. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: a randomized phase II study. Acta Oncol. 2014;53:939–44.CrossRefPubMed
6.
Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012;366:310–20.CrossRefPubMedPubMedCentral
7.
Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005;69(Suppl 3):25–33.CrossRefPubMed
8.
Uehara K, Hiramatsu K, Maeda A, Sakamoto E, Inoue M, Kobayashi S, et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol. 2013;43:964–71.CrossRefPubMed
9.
10.
Rijcken E, Sachs L, Fuchs T, Spiegel HU, Neumann PA. Growth factors and gastrointestinal anastomotic healing. J Surg Res. 2014;187:202–10.CrossRefPubMed
11.
Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol. 2007;170:1807–16.CrossRefPubMedPubMedCentral
12.
Kube R, Mroczkowski P, Granowski D, Benedix F, Sahm M, Schmidt U, et al. Anastomotic leakage after colon cancer surgery: a predictor of significant morbidity and hospital mortality, and diminished tumour-free survival. Eur J Surg Oncol. 2010;36:120–4.CrossRefPubMed
13.
August DA, Serrano D, Poplin E. “Spontaneous”, delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol. 2008;97:180–5.CrossRefPubMed
14.
Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008;26:1830–5.CrossRefPubMed
15.
Starlinger P, Alidzanovic L, Schauer D, Maier T, Nemeth C, Perisanidis B, et al. Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation. Br J Cancer. 2012;107:961–6.CrossRefPubMedPubMedCentral
16.
Kuzu MA, Koksoy C, Kale T, Demirpence E, Renda N. Experimental study of the effect of preoperative 5-fluorouracil on the integrity of colonic anastomoses. Br J Surg. 1998;85:236–9.CrossRefPubMed
17.
van der Kolk BM, de Man BM, Wobbes T, Hendriks T. Is early post-operative treatment with 5-fluorouracil possible without affecting anastomotic strength in the intestine? Br J Cancer. 1999;79:545–50.CrossRefPubMedPubMedCentral
18.
Ozel L, Ozel MS, Toros AB, Kara M, Ozkan KS, Tellioglu G, et al. Effect of early preoperative 5-fluorouracil on the integrity of colonic anastomoses in rats. World J Gastroenterol. 2009;15:4156–62.CrossRefPubMedPubMedCentral
19.
Pavlidis ET, Ballas KD, Symeonidis NG, Psarras K, Koliakos G, Kouzi-Koliakos K, et al. The effect of bevacizumab on colon anastomotic healing in rats. Int J Colorectal Dis. 2010;25:1465–73.CrossRefPubMed
20.
Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther. 1999;288:371–8.PubMed
21.
Fuh G, Wu P, Liang WC, Ultsch M, Lee CV, Moffat B, et al. Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem. 2006;281:6625–31.CrossRefPubMed
22.
Christensen H, Oxlund H. Growth hormone increases the collagen deposition rate and breaking strength of left colonic anastomoses in rats. Surgery. 1994;116:550–6.PubMed
23.
Christoforidis JB, Wang J, Jiang A, Willard J, Pratt C, Abdel-Rasoul M, et al. The effect of intravitreal bevacizumab and ranibizumab on cutaneous tensile strength during wound healing. Clin Ophthalmol. 2013;7:185–91.CrossRefPubMedPubMedCentral
24.
Park HY, Kim JH, Park CK. VEGF induces TGF-beta1 expression and myofibroblast transformation after glaucoma surgery. Am J Pathol. 2013;182:2147–54.CrossRefPubMed
25.
Hawley PR, Faulk WP, Hunt TK, Dunphy JE. Collagenase activity in the gastro-intestinal tract. Br J Surg. 1970;57:896–900.CrossRefPubMed
26.
van der Flier M, Coenjaerts FE, Mwinzi PN, Rijkers E, Ruyken M, Scharringa J, et al. Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis. J Neuroimmunol. 2005;160:170–7.CrossRefPubMed
27.
Passot G, Dupre A, Rivoire M, Mohamed F, Bakrin N, Glehen O. Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model. Clin Transl Oncol. 2012;14:931–6.CrossRefPubMed
28.
Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, et al. Colon cancer, version 3.2014. J Natl Compr Cancer Netw JNCCN. 2014;12:1028–59.PubMed
Metadata
Title
The effects of bevacizumab on intestinal anastomotic healing in rabbits
Authors
Hayato Nakamura
Yukihiro Yokoyama
Keisuke Uehara
Toshio Kokuryo
Junpei Yamaguchi
Toyonori Tsuzuki
Masato Nagino
Publication date
01-12-2016
Publisher
Springer Japan
Published in
Surgery Today / Issue 12/2016
Print ISSN: 0941-1291
Electronic ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-016-1342-4

Other articles of this Issue 12/2016

Surgery Today 12/2016 Go to the issue

Original Article

Clinical value and pitfalls of fluorescent cholangiography during single-incision laparoscopic cholecystectomy

Original Article

Risk factors for early renal dysfunction following endovascular aortic aneurysm repair and its effect on the postoperative outcome

Original Article

Sublobar resection versus lobectomy for stage I non-small cell lung cancer: an appropriate choice in elderly patients?

Original Article

Introduction of the non-technical skills for surgeons (NOTSS) system in a Japanese cancer center

How to Do It

Omental flap after pelvic exenteration for pelvic cancer

How to Do It

Retroileal colorectal anastomosis after extended left colectomy: application for laparoscopic surgery